The initiation of coverage by Guggenheim with a Buy rating and a specific price target of $36 suggests a positive outlook for Pfizer's stock. This recommendation is likely to influence investor sentiment positively in the short term, as analyst ratings from reputable firms often do. The setting of a price target above the current trading price can serve as a bullish signal to the market, potentially driving up the stock price.